2023年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20230750

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (5): 468-471.doi: 10.35541/cjd.20230750

2023年系统性红斑狼疮研究新进展

罗帅寒天¹ 龙海¹ 陆前进^2，3

¹中南大学湘雅二医院皮肤性病科，长沙 410011；²中国医学科学院北京协和医学院皮肤病医院，南京 210042；³中国医学科学院免疫性皮肤病基础与转化研究重点实验室，南京 210042

收稿日期:2023-12-18 修回日期:2024-01-10 发布日期:2024-04-30
通讯作者: 陆前进 E-mail:qianlu5860@pumcderm.cams.cn
基金资助:
国家自然科学基金（81703133、82273540、81830097、32141004）；湖南省自然科学基金（2021JJ40856）；湖南省科技创新计划项目（2018RS3031）；长沙市科技计划项目（KQ1802002）；中国医学科学院中央级公益性科研院所基本科研业务费专项资金（2021-RC320-001、2020-RC320-003）；中国医学科学院医学与健康科技创新工程项目（CIFMS-2021-I2M-1-059）

Research advances in systemic lupus erythematosus in 2023

Luo Shuaihantian¹, Long Hai¹, Lu Qianjin^2,3

¹Department of Dermatology, the Second Xiangya Hospital of Central South University, Changsha 410011, China; ²Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China; ³Key Laboratory of Immunological Dermatology and Translational Research, Chinese Academy of Medical Sciences, Nanjing 210042, China

Received:2023-12-18 Revised:2024-01-10 Published:2024-04-30
Contact: Lu Qianjin E-mail:qianlu5860@pumcderm.cams.cn
Supported by:
National Natural Science Foundation of China （81703133, 82273540, 81830097, 32141004）; Natural Science Foundation of Hunan Province （2021JJ40856）; Hunan Science and Technology Innovation Project （2018RS3031）; Changsha Science and Technology Planning Project （KQ1802002）; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences （2021-RC320-001, 2020-RC320-003）; CAMS Innovation Fund for Medical Sciences （CIFMS-2021-I2M-1-059）

摘要/Abstract

摘要： 【摘要】系统性红斑狼疮是一种累及多个器官系统的复杂的自身免疫性疾病。2023年系统性红斑狼疮的发病机制、诊断和评估、治疗方案等方面取得了一系列重要的研究成果，本文综述主要代表性成果。

关键词: 红斑狼疮, 系统性, 长散在核元件-1, 无能自身反应性B细胞, 延胡索酸水合酶, 补体4, 烟酰胺

Abstract: 【Abstract】 Systemic lupus erythematosus is a classical autoimmune disease that affects multiple organs and systems. In 2023, a lot of new research progress was made in the pathogenesis, diagnosis, evaluation, and treatment of systemic lupus erythematosus. This review summarizes the major representative achievements.

Key words: Lupus erythematosus, systemic, Long interspersed nuclear elements-1, Anergic autoreactive B cells, Fumarate hydratase, Complement 4, Niacinamide

罗帅寒天龙海陆前进, . 2023年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2024,57(5):468-471. doi:10.35541/cjd.20230750

Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2023[J]. Chinese Journal of Dermatology, 2024, 57(5): 468-471.doi:10.35541/cjd.20230750

参考文献 25

［1］	Crow MK. Long interspersed nuclear elements （LINE⁃1）: potential triggers of systemic autoimmune disease［J］. Autoimmunity, 2010,43（1）:7⁃16. doi: 10.3109/08916930903374865.
［2］	Jiang Y, Zong W, Ju S, et al. Promising member of the short interspersed nuclear elements （Alu elements）: mechanisms and clinical applications in human cancers［J］. J Med Genet, 2019,56（10）:639⁃645. doi: 10.1136/jmedgenet⁃2018⁃105761.
［3］	Song Y, Li X, Wei X, et al. Human endogenous retroviruses as biomedicine markers［J］. Virol Sin, 2021,36（5）:852⁃858. doi: 10.1007/s12250⁃021⁃00387⁃7.
［4］	Cervantes⁃Ayalc A, Ruiz Esparza⁃Garrido R, Velázquez⁃Flores MÁ. Long interspersed nuclear elements 1 （LINE1）: the chimeric transcript L1⁃MET and its involvement in cancer［J］. Cancer Genet, 2020,241:1⁃11. doi: 10.1016/j.cancergen.2019. 11.004.
［5］	Sciamanna I, De Luca C, Spadafora C. The reverse transcriptase encoded by LINE⁃1 retrotransposons in the genesis, progression, and therapy of cancer［J］. Front Chem, 2016,4:6. doi: 10.3389/fchem.2016.00006.
［6］	Baldwin ET, van Eeuwen T, Hoyos D, et al. Structures, functions and adaptations of the human LINE⁃1 ORF2 protein. Nature［J］. 2024,626（7997）:194⁃206. doi: 10.1038/s41586⁃023⁃06947⁃z.
［7］	Tanaka S, Ise W, Baba Y, et al. Silencing and activating anergic B cells［J］. Immunol Rev, 2022,307（1）:43⁃52. doi: 10.1111/imr. 13053.
［8］	Dörner T, Szelinski F, Lino AC, et al. Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus［J/OL］. RMD Open, 2020,6（2）:e001258. doi: 10.1136/ rmdopen⁃2020⁃001258.
［9］	Liu Y, Zhang Z, Kang Z, et al. Interleukin 4⁃driven reversal of self⁃reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus［J］. Ann Rheum Dis, 2023,82（11）:1444⁃1454. doi: 10.1136/ard⁃2023⁃224453.
［10］	Zecchini V, Paupe V, Herranz⁃Montoya I, et al. Fumarate induces vesicular release of mtDNA to drive innate immunity［J］. Nature, 2023,615（7952）:499⁃506. doi: 10.1038/s41586⁃023⁃05770⁃w.
［11］	Kancherla P, Daneshvar M, Sager RA, et al. Fumarate hydratase as a therapeutic target in renal cancer［J］. Expert Opin Ther Targets, 2020,24（9）:923⁃936. doi: 10.1080/14728222.2020.180 4862.
［12］	Cheng J, Liu Y, Yan J, et al. Fumarate suppresses B⁃cell activation and function through direct inactivation of LYN［J］. Nat Chem Biol, 2022,18（9）:954⁃962. doi: 10.1038/s41589⁃022⁃01052⁃0.
［13］	Zhao Y, Li Y, Zhao D, et al. Fumarate hydratase⁃specific T cell response in Chinese patients with autoimmune hepatitis［J］. Clin Res Hepatol Gastroenterol, 2018,42（4）:339⁃346. doi: 10.1016/j.clinre.2017.12.003.
［14］	Hooftman A, Peace CG, Ryan DG, et al. Macrophage fumarate hydratase restrains mtRNA⁃mediated interferon production［J］. Nature, 2023,615（7952）:490⁃498. doi: 10.1038/s41586⁃023⁃05720⁃6.
［15］	Hou Y, Wang L, Luo C, et al. Clinical characteristics of early⁃onset paediatric systemic lupus erythematosus in a single centre in China［J］. Rheumatology （Oxford）, 2023,62（10）:3373⁃3381. doi: 10.1093/rheumatology/kead086.
［16］	Crisafulli F, Andreoli L, Zucchi D, et al. Variations of C3 and C4 before and during pregnancy in systemic lupus erythematosus: association with disease flares and obstetric outcomes［J］. J Rheumatol, 2023,50（10）:1296⁃1301. doi: 10.3899/jrheum.2022⁃1135.
［17］	Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update［J］. Ann Rheum Dis, 2024,83（1）:15⁃29. doi: 10.1136/ard⁃2023⁃224762.
［18］	Wohlrab J, Kreft D. Niacinamide ⁃ mechanisms of action and its topical use in dermatology［J］. Skin Pharmacol Physiol, 2014,27（6）:311⁃315. doi: 10.1159/000359974.
［19］	Nouh AH, Elshahid AR, Kadah AS, et al. Topical niacinamide （nicotinamide） treatment for discoid lupus erythematosus （DLE）: a prospective pilot study［J］. J Cosmet Dermatol, 2023,22（5）:1647⁃1657. doi: 10.1111/jocd.15628.
［20］	Sterner RC, Sterner RM. CAR⁃T cell therapy: current limitations and potential strategies［J］. Blood Cancer J, 2021,11（4）:69. doi: 10.1038/s41408⁃021⁃00459⁃7.
［21］	Ying Z, Yang H, Guo Y, et al. Relmacabtagene autoleucel （relma⁃cel） CD19 CAR⁃T therapy for adults with heavily pretreated relapsed/refractory large B⁃cell lymphoma in China［J］. Cancer Med, 2021,10（3）:999⁃1011. doi: 10.1002/cam4.3686.
［22］	Ying Z, Yang H, Guo Y, et al. Long⁃term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B⁃cell lymphoma: updated results of the RELIANCE study［J］. Cytotherapy, 2023,25（5）:521⁃529. doi: 10.1016/j.jcyt.2022.10.011.
［23］	Lin Z, Zuo C, Jiang Y, et al. Cost⁃effectiveness analysis of relmacabtagene autoleucel for relapsed or refractory large B⁃cell lymphoma in China［J］. Value Health Reg Issues, 2023,37:41⁃48. doi: 10.1016/j.vhri.2023.03.006.
［24］	Hurst C, Soto M, Vina ER, et al. Renin⁃angiotensin system⁃modifying antihypertensive drugs can reduce the risk of cardiovascular complications in lupus: a retrospective cohort study［J］. Am J Med, 2023,136（3）:284⁃293.e4. doi: 10.1016/j.amjmed.2022.11.016.
［25］	Roccatello D, Fenoglio R, Caniggia I, et al. Daratumumab monotherapy for refractory lupus nephritis［J］. Nat Med, 2023,29（8）:2041⁃2047. doi: 10.1038/s41591⁃023⁃02479⁃1.

[1]	徐经纬陈爽郭克磊韩立卞华. 微小RNA调控系统性硬皮病纤维化相关信号通路的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230730-e20230730.
[2]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[3]	王瑞霞曲岩磊艾文锦闫琳曲才杰史同新. 非大疱性嗜中性红斑狼疮1例[J]. 中华皮肤科杂志, 2024, 0(2): 20230213-e20230213.
[4]	罗帅寒天龙海陆前进. 2022年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2023, 56(3): 266-269.
[5]	林子沅庞天怡武静文靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220271-e20220271.
[6]	王琪坚哲. 间充质干细胞三维培养技术及其在皮肤病治疗中的应用进展[J]. 中华皮肤科杂志, 2023, 0(2): 20230083-e20230083.
[7]	蒋佳怡王大光. 系统性疾病致甲改变机制研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220078-e20220078.
[8]	胡颖焦晴晴. 记忆性T细胞在慢性自身免疫性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20230193-e20230193.
[9]	万立陈金波姜倩陈红英胡彬陈柳青. 反射式共聚焦显微镜在界面皮炎中的应用研究进展[J]. 中华皮肤科杂志, 2023, 56(10): 982-985.
[10]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[11]	罗帅寒天龙海陆前进, . 2021年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2022, 55(4): 369-372.
[12]	中国医师协会皮肤科医师分会自身免疫性疾病学组. [开放获取] 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[13]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[14]	罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545.
[15]	渠莉田苏惠春程波. 特应性皮炎与系统性疾病相关性的研究进展[J]. 中华皮肤科杂志, 2021, 54(5): 463-466.

2023年系统性红斑狼疮研究新进展

Research advances in systemic lupus erythematosus in 2023

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

Metrics

本文评价

推荐阅读 10